Koyalta, D., Charpentier, C., Beassamda, J., Rey, E., Si-Mohamed, A., Djemadji-Oudjeil, N. and Belec, L. (2009) High Frequency of Antiretroviral Drug Resistance among HIV-Infected Adults Receiving First-Line Highly Active Antiretroviral Therapy in N’Djamena, Chad. Clinical Infectious Diseases, 49, 155-159. http://dx.doi.org/10.1086/599611

has been cited by the following article:

• TITLE: Immunovirologic Evaluation of Triomune (Lamivudine, Stavudine and Nevirapine) Antiretroviral Therapy in First Line HIV-1 Adult Patients in N’Djamena, Chad

  AUTHORS: Chatté Adawaye, Kamangu Erick, Soudy I. Djibrine, Aoudalkarim Moussa Chahad, Ali Mahamat Moussa, Tchombou HZ Bertin, Vaira Dolores, Moutschen Michel

  KEYWORDS: Plasma, Viral Load, Triomune, Antiretroviral Therapy, Virological Failure, ARVs, HIV-1, First Line

  JOURNAL NAME: World Journal of AIDS, Vol.4 No.3, August 18, 2014

  ABSTRACT: Contexte:The fight against HIV/AIDS epidemics is one of the greatest challenges of this century. The epidemic affects generally under-developed countries, and Sub-Saharan Africa are the most concerned. The combined marketed form known as Triomune was used as first-line treatment in several sub-Saharan African Countries (60% of VIH infected people), including Chad. However, no evaluation has been done for that treatment in the country. Objective: To evaluate the efficacy and safety immuno-virological of Triomune at the General Hospital in N’Djamena/Chad. Methods: 48 HIV-1 positive patients eligible for ARV treatment were enrolled in our study, and they have been then followed for 8 months. We have measured in these patients the CD4 cell count before treatment and at the 8th month of treatment. After 8 months of treatment, we have also evaluated the Lymphocyte T CD4 and the plasma viral load (VL). Comparisons of means of CD4 lymphocytes and plasma CV (≥1000 copies/ml) were used to define treatment failure.Results:48 patients were under Triomune regime. The average CD4 count was decreased from 462 ± 179.22 [56 - 981] cells/mm3before treatment to 327.23 ± 153.77 [10 - 1008] cells/mm3at the 8th month of treatment. The mean plasma viral load for patients was 66008.62 copies/ml. The failure rate to Triomune was 43.75% (21/48).Conclusion:Aside from the side effects already described for Triomune, our study reveals a high treatment failure rate. Hence, there is the need of regular revisions of therapeutic regime administer in the first intention.